Reduced levels of plasma kisspeptin during the antenatal booking visit are associated with increased risk of miscarriage

CN Jayasena1*, A Abbara1*, C Izzi-Engbeaya1, AN Comninos1, RA Harvey2, J Gonzalez Maffe3, Z Sarang1, Z Ganiyu-Dada1, Al Padilha2, M Dhanjal4, Prof C Williamson5, Prof L Regan6, Prof, MA Ghatel1, Prof SR Bloom1 & Prof WS Dhillo1

1Section of Investigative Medicine, Imperial College London. 2Medical Oncology Laboratory, Charing Cross Hospital Campus, Imperial College NHS Healthcare Trust. 3Imperial Clinical Trials Unit, Imperial College London. 4Department of Obstetrics & Gynaecology, Queen Charlotte’s Hospital, Imperial College NHS Healthcare Trust. 5Department Obstetrics & Gynaecology, King’s College London. 6Department of Obstetrics & Gynaecology, St. Mary’s Hospital, Imperial College NHS Healthcare Trust.

CONTEXT: Kisspeptin is a recently identified hormone encoded by the KISS1 gene, playing a critical role in human reproduction. Plasma kisspeptin levels rise dramatically during normal pregnancy due to placental synthesis, which implicates it as a potential tool for assessing risks of pregnancy complications. No previous prospective study has investigated the association between plasma kisspeptin and risk of miscarriage.

OBJECTIVE: To determine whether a single plasma kisspeptin or serum hCG measurement in asymptomatic women attending their booking antenatal visit are associated with miscarriage.

DESIGN: Prospective cohort study

SETTING: Tertiary obstetric centre

PARTICIPANTS: 993 asymptomatic pregnant women ≥6 weeks gestation attending routine antenatal booking visit were recruited between January 2010 and December 2012.

MAIN OUTCOME MEASURES: Plasma kisspeptin and serum hCG were measured during antenatal booking visit. Pregnancy outcome was recorded prospectively.

RESULTS: Plasma kisspeptin correlated with gestation ($r^2=0.57; P<0.0001$). Gestational age-corrected (multiples of median, MoM) plasma kisspeptin was 60.4% lower ($P<0.001$), and MoM-hCG was 36.1% lower ($P<0.001$) in women later diagnosed with miscarriage compared with women without miscarriage. Increased plasma kisspeptin was associated with reduced miscarriage risk, even after adjusting for age, BMI, gestational age, smoking and blood pressure (OR 0.13 [0.08–0.22], $P=0.0001$). Kisspeptin had a higher diagnostic performance for miscarriage than hCG (ROC-AUC: 0.899 vs. 0.775, plasma kisspeptin; 0.775 ± 0.040, serum hCG, $P<0.01$ vs. plasma kisspeptin).

CONCLUSION: Our data suggest for the first time that a single plasma kisspeptin measurement taken during the antenatal booking visit provides a potential novel marker for identifying asymptomatic pregnant women ≥6 weeks gestation at increased risk of miscarriage.

Miscarriage is defined as spontaneous pregnancy loss prior to 24 weeks of gestation (1). Ten to twenty percent of all clinically recognized pregnancies end in miscarriage (2, 3). Women affected by a single miscarriage not
only suffer devastating emotional consequences (4), but are also at increased risk of developing serious antenatal morbidities such as preeclampsia and preterm delivery during subsequent pregnancies (5–7). Prior to 6 weeks gestation, most miscarriages result from cytogenetic abnormalities in the embryo such as chromosomal trisomy (8). However later during gestation, other causes of miscarriage, such as placental insufficiency, intrauterine infection and thrombosis, become more common. There are currently no proven treatments to prevent noncytogenetic causes of miscarriage; however this may reflect that there is currently no established marker to identify women at increased risk of miscarriage. Fetal viability may be estimated using serial measurement of serum hCG during multiple hospital visits; however approximately 20% of cases resulting in miscarriage are also associated with rising levels of serum hCG which are typical of viable pregnancy and the clinical utility is limited (9). There is therefore both a delay and a high degree of uncertainty in diagnosing miscarriage using this approach, which can be a source of further distress for affected couples.

Abnormal placentation (placental development) is found in two-thirds of cases of miscarriage (10, 11). The recently identified hormone kisspeptin has been suggested to play an important regulatory role in placentaion. Kisspeptin consists of a group of arginine-phenylalanine (RF) amide peptides encoded by the KISS1 gene which bind to the kisspeptin receptor (12–15). Kisspeptin is expressed most abundantly in the syncytiotrophoblast cells of the placenta, where it may regulate invasion into the maternal uterine wall (14, 16, 17). Kisspeptin is also expressed in areas of the brain such as hypothalamus, amygdala and caudate nucleus, in addition to the pituitary, pancreas, adipose, testis, lymphocytes and spleen (13, 15). Circulating levels of kisspeptin increase gradually during pregnancy, becoming markedly elevated up to 7000-fold during later pregnancy when compared with nonpregnant women (18). Recent case-control studies have suggested that circulating kisspeptin levels are reduced in women with pre-eclampsia and intra-uterine growth retardation (IUGR), when compared with uncomplicated pregnancies (19, 20). Levels of placental kisspeptin expression are significantly lower in women with recurrent miscarriage when compared with placental tissue in electively terminated pregnancies (21). This preliminary evidence therefore suggests that low placental kisspeptin levels may be associated with increased risk of miscarriage or other serious obstetric complications if the fetus survives. It is currently not known whether plasma kisspeptin levels during pregnancy are associated with miscarriage.

We conducted a prospective cohort study including over 900 women at a single obstetric center, to determine whether levels of plasma kisspeptin or serum hCG are associated with miscarriage in asymptomatic women ≥ 6 weeks gestation attending their booking antenatal visit.

Materials and Methods

This study was performed in accordance with the Declaration of Helsinki following ethical approval (West London Research Ethics Committee; Q0406/80). Women attending routine antenatal booking visit at Queen Charlotte’s and Chelsea Hospital London, UK were invited to participate between January 2010 and December 2012. Nine hundred and ninety-three pregnant women attending their routine antenatal booking clinic appointment were recruited. Following written informed consent, a single blood sample was taken for measurement of plasma kisspeptin and serum hCG. Women with renal failure were excluded due to assay interference with kisspeptin measurement. Emergency admissions or cases of suspected miscarriage were excluded. Twelve women were lost to follow-up, despite attempts of obstetric staff to contact these women. The remaining 981 women were followed-up until the outcome of pregnancy was known.

Patient details and outcomes:

All pregnancies were dated according to a dating ultrasound scan (typically at 8–14 weeks gestation) performed in the antenatal clinic. Ultrasound parameters from a 20 week fetal anomaly scan, patient-held clinical notes, and hospital electronic records were collated to establish whether miscarriage or live birth had occurred. Miscarriage was either diagnosed using ultrasound scanning, or was self-reported. Patient details are summarized in Table 1.

Measurement of plasma kisspeptin immunoreactivity

Measurement of plasma kisspeptin immunoreactivity (IR) was performed using an established in-house radioimmunoassay (RIA) previously developed in our laboratory (22, 23). In brief, a known quantity of I-125 labeled kisspeptin-54 peptide is used to compete with an unknown quantity of kisspeptin for binding to a limited quantity of antibody derived from sheep antiserum raised against kisspeptin. Radioactivity of charcoal-separated antibody-peptide complexes is inversely proportional to levels of kisspeptin in the sample. The antibody cross-reacts 100% with human kisspeptin-54, kisspeptin-14, and kisspeptin-10 and less than 0.01% with other related RF amide proteins, including prolactin-releasing peptide, RF amide-related peptide (RFRP) 1, 2
RFRP2, RFRP3, QRFP43, neuropeptide FF, and neuropeptide AF. The limit of detectability was 2 pmol/L, and the intra- and interassay coefficients of variation were 8.3 and 10.2%, respectively.

**Measurement of total hCG immunoreactivity**

Measurement of plasma hCG was performed using the Siemens Immulite 2000 total immunometric hCG assay run on board the Siemens Immulite 2000 instrument (Siemens Healthcare Diagnostics 1717 Deerfield Road, Deerfield, IL, USA). According to the manufacturer’s kit insert the analytical sensitivity of the assay is 0.4 IU/L. Performance is monitored daily and internal quality control (QC) samples ranging 5–250 IU/L yield intra- and interassay coefficients of variation (CV) of less than 10%. Studies using the latest WHO standard preparations for common hCG protein variants have demonstrated that the Immulite 2000 assay detects all hCG isoforms, but is associated with relative slight overestimation of hCGβ and underdetection of the hCGβ core fragment isoforms (24, 25).

**Data Analysis and Statistics:**

Sample size aimed to recruit sufficient cases to determine the association of plasma kisspeptin with miscarriage, correcting for confounding variables that may confer an increased risk of miscarriage (ie, participant age, gestational age, body mass index (BMI) [BMI], smoking, diastolic blood pressure (BP), and systolic BP). Data was analyzed using Prism 5 (GraphPad, California). In order to account for variation in circulating kisspeptin and hCG levels during pregnancy, we calculated multiple of median (MoM) levels of each hormone measurement during the gestation when blood was collected. Data are presented as mean±standard deviation (s.d.). Pairs of means were analyzed using the unpaired two-tailed t test. Multiple means were compared using one-way ANOVA with Tukey’s Multiple Comparison Test. Logistic regression was used to analyze associations between plasma kisspeptin and hCG with risk of miscarriage; the rationale for log transformation was to reduce the variability in kisspeptin levels (particularly at high levels), in order to better study the association with risk of miscarriage. P < .05 was considered statistically significant.

**Results**

**Baseline characteristics of pregnant subjects attending their antenatal booking visit**

Nine hundred and ninety-three women attending antenatal clinic for a routine booking antenatal appointment were recruited to the study. Twelve women (ie, 1% of the sample) were lost to follow-up, so their data was excluded from all analyses. The remaining 981 women had a mean gestation of 11.2 weeks (range 5.9–22.1) (see Table 1 for characteristics). Thirty-two pregnancies were multiple (thirty twin pregnancies of which six were monochorionic; two triplet pregnancies). No participants were attending as an emergency, or presented with symptoms of threatened miscarriage such as abdominal pain or vaginal bleeding.

**Distribution of plasma levels of kisspeptin in pregnant women at the antenatal booking visit with a singleton pregnancy not resulting in miscarriage**

In single pregnancies not resulting in miscarriage, levels of plasma kisspeptin increased steadily during each week of gestation during the first trimester of pregnancy (Figure 1A). Plasma kisspeptin in single pregnancies was highly significantly and positively correlated with the gestational week of pregnancy (r = 0.57; P < .0001) (Figure 1B). Serum hCG in single pregnancies had a complex relationship with gestational age; levels peaked around the eighth gestational week, before reducing with increasing gestational week. (Figure 1C-D). Log transformation of serum hCG in single pregnancies suggested a significant and negative correlation with gestational age (r = -0.41, 95% CI –0.47 to –0.36) (data not shown).

In singleton pregnancies not resulting in miscarriage, MoM plasma kisspeptin levels were classified according to duration of sample storage at –20°C prior to kisspeptin...
measurement (between 10 and 31 months; Supplemental Figure 2). No significant differences between MoM kisspeptin levels among any group were observed ($P = .07$).

**Relationship between plasma kisspeptin and miscarriage in singleton pregnancies**

Fifty of the 981 (5.1%) women attending antenatal clinic with a singleton pregnancy were diagnosed with miscarriage after recruitment to the study (Supplemental Table 1). Multiples of Median (MoM; gestation-corrected) kisspeptin levels were 60% lower in women with a singleton pregnancy who later experienced miscarriage when compared with unaffected pregnancies (MoM kisspeptin: $1.06 \pm 0.42$, singleton-no-miscarriage, $0.42 \pm 0.39$, singleton-with-miscarriage, $P < .001$ vs. singleton-no-miscarriage) (Figure 2A). By comparison, MoM hCG levels were only 36% lower in singleton pregnancies during miscarriage when compared with singleton pregnancies which did not result in miscarriage (MoM kisspeptin: $1.08 \pm 0.47$, singleton-no-miscarriage, $0.69 \pm 1.35$, singleton-with-miscarriage, $P < .001$ vs. singleton-no-miscarriage) (Figure 2B). Receiver operator characteristic (ROC) curve analysis suggested that kisspeptin had a higher diagnostic performance with respect to miscarriage when compared with hCG (ROC area under curve: $0.899 \pm 0.025$, kisspeptin; $0.775 \pm 0.040$, hCG, $P < .01$ vs. kisspeptin) (Figure 2C-D). A kisspeptin threshold of 1630 pmol/L had 86% sensitivity (95% CI: 73%–94%) and 70% specificity (95% CI: 67%–73%) for detecting miscarriage, and a kisspeptin threshold of 1463 pmol/L had an 80% (95% CI: 66%–90%) sensitivity and a 75% (95% CI: 72%–78%) specificity for miscarriage. Patients with kisspeptin $< 1630$ pmol/L had a 13.8% chance of miscarriage being subsequently diagnosed (ie, 13.8% positive predictive value (PPV)), whereas patients with kiss-
peptin > 1630 pmol/L had a 1.0% chance of miscarriage being subsequently diagnosed (ie, 99.0% negative predictive value (NPV)).

Kisspeptin increased to a significantly lesser extent with gestational age, in the cohort of women who experienced miscarriage when compared with the cohort of women with uncomplicated pregnancy (slope coefficient for increase in plasma kisspeptin [pmol/L/wk]: 305 ± 15, singleton-without-miscarriage; 94 ± 30, singleton-with-miscarriage; \( F = 25.2, DF_n = 1, DF_d = 945, P < .0001 \)) (Figure 3A). Logistic regression analysis was performed to investigate whether the relationship between kisspeptin and miscarriage was independent of known confounders (Table 2). The unadjusted model revealed that the odds of experiencing a miscarriage decreased by 89% (OR = 0.11; 95% CI: 0.07–0.17; \( P < .0001 \)) for each 10-fold increase in kisspeptin. After adjustment for subject age, gestation, smoking, BP, and BMI, the odds of experiencing miscarriage decreased by 87% (OR = 0.13; 95% CI: 0.08–0.22; \( P < .0001 \)) for each 10-fold increase in kisspeptin.

**Combined testing of kisspeptin with hCG**

Logistic regression analysis was performed to explore if the diagnostic accuracy of using combined kisspeptin and hCG levels was superior to kisspeptin alone. Combined kisspeptin and hCG measurement (OR = 0.10; 95% CI: 0.06–0.17; \( P < .0001 \)) had similar diagnostic accuracy when compared with kisspeptin measurement alone (OR = 0.11; 95% CI: 0.07–0.17; \( P < .0001 \)).

**Relationship of plasma kisspeptin with time to diagnosis of miscarriage**

Ultrasoundography confirmed fetal viability in 13/50 pregnancies who later miscarried, an average of 34.8 ± 8 days (Figure 3A).

**Table 2.** Logistic regression model for miscarriage risk in relation to plasma kisspeptin in women during the antenatal booking visit. The unadjusted odds of experiencing a miscarriage decrease by 89% (OR = 0.11; 95% CI: 0.07 to 0.17; \( P = 0.0001 \)) for each unit increase in (Log) plasma kisspeptin. After adjusting the model by age, gestational age (weeks) and BMI, we found that the effects of kisspeptin changes slightly. After adjustment for confounders, the odds of experiencing a miscarriage still decrease by 87% (OR = 0.13; 95% CI: 0.08 to 0.22; \( P = 0.0001 \)) for each unit increase in (Log) kisspeptin.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Unadjusted</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Log) Kisspeptin</td>
<td>0.11 (0.07, 0.17)</td>
<td>0.14 (0.08, 0.22)</td>
<td>0.19 (0.08, 0.22)</td>
<td>0.15 (0.08, 0.22)</td>
</tr>
<tr>
<td>Age</td>
<td>( P &lt; 0.0001 )</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>BMI</td>
<td>1.02 (0.94, 1.11)</td>
<td>0.96 (0.88, 1.05)</td>
<td>0.97 (0.89, 1.07)</td>
<td>0.97 (0.89, 1.07)</td>
</tr>
<tr>
<td>Gestation age</td>
<td>0.46 (0.40, 0.53)</td>
<td>0.46 (0.40, 0.53)</td>
<td>0.55 (0.49, 0.63)</td>
<td>0.55 (0.49, 0.63)</td>
</tr>
<tr>
<td>Smoking</td>
<td>1.31 (0.24, 7.23)</td>
<td>0.30 (0.11, 0.85)</td>
<td>0.10 (0.01, 0.87)</td>
<td>0.10 (0.01, 0.87)</td>
</tr>
<tr>
<td>Diastolic Blood Pressure</td>
<td>0.99 (0.98, 1.10)</td>
<td>1.00 (0.99, 1.01)</td>
<td>0.99 (0.96, 1.14)</td>
<td>0.99 (0.96, 1.14)</td>
</tr>
<tr>
<td>Systolic Blood Pressure</td>
<td>0.99 (0.98, 1.00)</td>
<td>1.00 (0.99, 1.00)</td>
<td>1.00 (0.99, 1.00)</td>
<td>1.00 (0.99, 1.00)</td>
</tr>
</tbody>
</table>

\[ \text{AUC}=90\% \] (Figure 2).
6.8 days (range 2–85 days) following kisspeptin measurement. We investigated in more detail the length of time following kisspeptin and hCG measurement, when patients were diagnosed with miscarriage (Figure 3).

**Kisspeptin.** Compared with unaffected pregnancies, kisspeptin was significantly lower in women who experienced miscarriage when compared with unaffected pregnancies; lowest levels were observed in patients miscarrying during the first week following blood measurement (kisspeptin in pmol/L: 2250 ± 1045 no miscarriage; 195 ± 116 miscarriage < 7 days, P < .001 vs. no miscarriage). Intermediate values were obtained in patients miscarrying between 7 to 21 days following the blood test (kisspeptin in pmol/L: 709 ± 750 miscarriage 7–21 days; P < .001 vs. no miscarriage and P < .001 vs. miscarriage < 7 days). Kisspeptin levels in women miscarrying > 21 days following the blood test were higher than the other miscarriage groups but significantly lower than the group that did not miscarry (kisspeptin in pmol/L: 951 ± 716 miscarriage > 21 days, P < .001 vs. no miscarriage) (Figure 3A). There was a significant correlation between kisspeptin and the time following blood measurement that miscarriage was diagnosed (r² = 0.23, P < .001) (Figure 3B).

**hCG.** This was only lower in women who experienced miscarriage when compared with unaffected pregnancy, if blood measurement was within 3 weeks prior to the diagnosis of miscarriage (hCG in IU/Lx1000: 85.1 ± 39.3, no miscarriage; 17.2 ± 21.6 miscarriage < 7 days, P < .05 vs. no miscarriage; 51.8 ± 55.6 miscarriage 7–21 days, P < .05 vs. no miscarriage; 63.8 ± 37.0 miscarriage > 21 days, P = ns vs. < 7 days) (Figure 3C). hCG did not correlate significantly with the time following blood measurement that miscarriage was diagnosed (r² = 0.028, P = ns) (Figure 3D).

**Relationship between plasma kisspeptin and miscarriage in multiple pregnancies**

Thirty-two of the subjects had multiple pregnancies. We therefore investigated whether and how the observed relationship between kisspeptin and viability of pregnancy, might also apply to multiple pregnancies. MoM kisspeptin was significantly higher in twin pregnancies unaffected by miscarriage when compared with single pregnancies unaffected by miscarriage (MoM kisspeptin: 1.06 ± 0.42, singleton-no-miscarriage, 1.64 ± 0.54, twin-no-miscarriage, P < .001 vs. singleton-no-miscarriage; 2.09 ± 0.26, triplet-no-miscarriage, P < .05 vs. singleton-no-miscarriage) (data not shown). In pregnancies uncomplicated by miscarriage, MoM hCG was significantly higher in twin pregnancy, but not triplet pregnancy when compared with single pregnancy (MoM hCG: 1.08 ± 0.47, singleton-no-miscarriage, 1.70 ± 0.49, twin-no-miscarriage, P < .001 vs. singleton-no-miscarriage; 1.88 ± 0.27, triplet-no-miscarriage, P = ns vs. twin-no-miscarriage) (data not shown). Ten of the thirty twin pregnancies and neither of the triplet pregnancies resulted in death of a single fetus. Death of a single fetus during twin pregnancy significantly reduced MoM kisspeptin and MoM hCG to levels comparable with successful singleton pregnancy (MoM kisspeptin: 1.06 ± 0.42, singleton-no-miscarriage; 1.15 ± 0.58, twin pregnancy with miscarriage of one fetus, P = ns vs. singleton-no-miscarriage) (MoM hCG: 1.08 ± 0.47, singleton-no-miscarriage; 1.23 ± 0.84, P = ns vs. singleton-no-miscarriage) (data not shown).

**Discussion**

Miscarriage is a tragic event, occurring most often before the sixth week of gestation due to nonviable chromosomal defects (8). Miscarriages after the sixth week of gestation are less common, but are more strongly associated with identifiable pathologies such as intrauterine infection and autoimmune disorders. It is therefore important to investigate whether simple and safe tests can be developed to identify pregnancies at high risk of miscarriage; as this could improve the quality of information given to patients, facilitate enhanced or targeted obstetric surveillance, and potentially improve obstetric outcomes. Kisspeptin has been recently identified as a hormone essential for fertility, pubertal development, and an important regulator of placental invasion. We report the results of the first large study of plasma kisspeptin levels at the booking antenatal visit. Our data suggest for the first time that plasma kisspeptin at antenatal booking visit is dramatically reduced in asymptomatic women ≥ 6 weeks gestation who later experience miscarriage when compared with unaffected pregnancies.

A rising level of serum hCG measured during multiple hospital visits is currently used to assess fetal viability during early pregnancy (26). However, this approach is only valid if performed before the eighth gestational week, when serum hCG levels are still rising, as our data and previous reports demonstrate (27). Furthermore, serum hCG is in general not used as a biomarker for pregnancy viability beyond the first trimester of pregnancy (28). Our data indicates that a single measurement of either serum hCG or kisspeptin ≥ 6 weeks gestation helps discriminate between viable and nonviable pregnancies, but plasma kisspeptin had superior diagnostic performance. In singleton pregnancies, a first trimester kisspeptin level of < 1463 pmol/L had an 80% (95% CI: 66%–90%) sensitiv-
Mean plasma kisspeptin level was higher in twin pregnancies and highest in triplet pregnancies. However, the death of a single fetus in a twin pregnancy was associated with a mean plasma kisspeptin level that was comparable to levels measured in viable singleton pregnancies. Taken together these findings suggest that circulating kisspeptin levels are derived solely from functioning placental tissue and directly reflect viable placental tissue volume. In keeping with this the high plasma kisspeptin levels during pregnancy fall to low nonpregnant levels within days of delivery of the baby and passing of the placenta (18). These observations are also in keeping with the excellent performance of kisspeptin as a biomarker for miscarriage in women ≥ 6 weeks gestation in our study.

Our observation that the slope-coefficient for correlation of kisspeptin levels with time of gestation across the cohort of women who experienced miscarriage was significantly lower than for those who had an unaffected pregnancy, suggests that a higher rate of increase in circulating plasma kisspeptin would be expected in a viable as compared with a failing pregnancy. It would be interesting therefore to examine this directly in a further study in which serial measurements of kisspeptin in individual patients would be collected. The serial measurements could then be used to derive kinetic parameters that could further enhance the diagnostic performance of kisspeptin measurement for assessment of fetal viability. Another
possibility would be to compare absolute and kinetic parameters for both hCG and kisspeptin measurement to determine optimal sampling times and an optimal combination to maximize discrimination.

In our study women were recruited at their routine antenatal booking visit, therefore blood samples were not collected during the earliest stages of pregnancy (ie, <6 weeks gestation). Further studies are needed to determine if the high observed performance of kisspeptin to detect miscarriage remains true during earlier gestation. It is reassuring that follow-up data was available on fetal viability in the vast majority (ie, 99%) of subjects included in our study; however we excluded 12 patients that were lost to follow-up who may (or may not) have suffered miscarriage. This study was carried out in a tertiary obstetric center that provides care for women with low and high-risk pregnancies as well as pregnancies that resulted from natural and assisted conception, therefore the results may be generalized to similar populations of pregnant women. During the current study, samples were stored at −20°C between 10 and 31 months prior to kisspeptin measurement. We therefore examined whether levels of plasma kisspeptin were related to the duration of storage. There was no significant difference between MoM kisspeptin levels among samples stored for 10, 27, 28, 29, 30 and 31 months in patients with singleton pregnancies that did not miscarry. Our data therefore suggest that the duration of sample storage did not significantly affect plasma kisspeptin levels.

In summary, we have performed the largest study to date, prospectively determining levels of plasma kisspeptin in a large cohort of pregnant women attending their antenatal booking visit. Our data suggest that plasma kisspeptin measurement in asymptomatic women ≥6 weeks gestation at antenatal booking visit, either alone or in combination with hCG, may be associated with miscarriage risk.

Acknowledgments

Address all correspondence and requests for reprints to: Corresponding author for proof and reprints: Prof. Waljit S. Dhillo, Department of Investigative Medicine, Imperial College London, sixth Floor, Commonwealth Building, Hammersmith Hospital, Du Cane Road, London W12 ONN, UK., Tel: +44 208 383 3242, Fax: +44 208 383 3142, w.dhillo@imperial.ac.uk.

*joint first authors

Declaration of Interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi disclosure.pdf (available on request from the corresponding author) and declare that (1) none of the authors have any relationships with companies that might have an interest in the submitted work in the previous 3 years; (2) none of the authors’ spouses, partners, or children have a financial relationship that may be relevant to the submitted work; and (3) none of the authors have a nonfinancial interest that may be relevant to the submitted work.

This work was supported by Funding: CNJ is supported by an NIHR Clinical Lectureship and Academy of Medical Science Starter Grant, AA is supported by a Wellcome Clinical Research Training Fellowship, CI is supported by an NIHR Academic Clinical Fellowship, ANC is supported by a Wellcome/GSK Clinical Research Fellowship, WSD is supported by an NIHR Career Development Fellowship. The Department of Investigative Medicine is supported by the NIHR Imperial Biomedical Research Centre. We are grateful to the Women’s Health Research Centre at Imperial College, and Imperial NIHR Biomedical Research Centre at Imperial College Healthcare NHS Trust for providing infrastructure for this study.

References

tanabe T, Asada M, Yamada T, Suenga M, Kitada C, Usuki S, Kurokawa T, Onda H, Nishimura O, Fujino M. Metastasis sup-
15. Muir AI, Chamberlain L, Elkhourbay NA, Michalovich D, Moore DJ, Calamari A, Szekeres PG, Sarau HM, Chambers JK, Murdoc-
17. Roseweir AK, Katz AA, Millar RP. Kisspeptin-10 inhibits cell mi-
19. Logie JJ, Denison FC, Riley SC, Ramaehandran R, Ramachandran R, Nijher GK, Amber V, Kokkinos A, Donald-
son M, Ghatei MA, Bloom SR. Kisspeptin-54 stimulates gonado-
tropin release most potently during the preovulatory phase of the menstrual cycle in women. J Clin Endocrinol Metab. 2007;92:
3958–3966.
20. Sturgeon CM, Berger P, Bidart JM, Birken S, Burns C, Norman RJ, Stenman UH. IFCC Working Group on hCG. Differences in recog-
nition of the 1st WHO international reference reagents for hCG-
21. Harvey RA, Mitchell HD, Stenman UH, Blankenstein MA, Nustad K, Stieber P, Stewart W, Savage PM, Seckl MJ, Braunstein GD. Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tu-
23. Althman H, Schroder J, Fraser R, Koskimies A, Halila H, Stenman UH. Choriogonadotropin and its beta subunit separated by hydro-
phobic-interaction chromatography and quantified in serum during pregnancy by time-resolved immunofluorometric assays. Clin
24. National Institute for Health and Care Excellence. Ectopic preg-